Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

PHASE3CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Actinic Keratosis
Interventions
DRUG

imiquimod cream

Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period

DRUG

placebo cream

cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period

Trial Locations (18)

11790

DermResearchCenter of New York, Stony Brook

27157

Wake Forest Univ School of Medicine, Winston-Salem

30263

MedaPhase, Inc., Newnan

33401

Palm Beach Dermatology, West Palm Beach

33705

Spencer Dermatology & Skin Surgery Center, Saint Petersberg

60077

Evanston Northwestern Healthcare, Skokie

68144

Skin Specialists PC, Omaha

75230

Dermatology Treatment and Research Center, Dallas

78229

Progressive Clinical Research, San Antonio

78759

DermResearch Inc., Austin

87106

Academic Dermatology Association, Albuquerque

90045

Dermatology Research Associates, Los Angeles

92123

Therapeutics Clinical Research, San Diego

97223

Oregon Medical Research Center, Portland

V3R6A7

Guildford Dermatology Specialists, Surrey

E1C 8X3

Clinique de Dermatologie, Moncton

L4M 6L2

Ultranova Skincare, Barrie

N2J 1C4

Probity Medical Research, Waterloo

Sponsors
All Listed Sponsors
lead

Graceway Pharmaceuticals, LLC

INDUSTRY